Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 18/20 | 0.80 |
| ▸ | BCR | P11274 | 16/20 | 0.80 |
| ▸ | PRKCA | P17252 | 8/20 | 0.80 |
| ▸ | SRC | P12931 | 9/20 | 0.76 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
| ▸ | PRKCG | P05129 | 1/20 | 0.71 |
| ▸ | PRKCB | P05771 | 1/20 | 0.71 |
| ▸ | PRKCH | P24723 | 1/20 | 0.71 |
| ▸ | PRKCI | P41743 | 1/20 | 0.71 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.71 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.71 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.71 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.71 |
| ▸ | EGFR | P00533 | 4/20 | 0.70 |
| ▸ | PRKACA | P17612 | 1/20 | 0.70 |
| ▸ | PRKACG | P22612 | 1/20 | 0.70 |
| ▸ | PRKACB | P22694 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27711429 | 0.99 | ABL1 (0.79) | ABL1BCRPRKCASRCPRKCD | |
| Hydrochloric Acid SCHEMBL27708725 | 0.98 | ABL1 (0.77) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL3747896 | 0.90 | CAMKK2 (0.80) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL4903516 | 0.89 | MAPK8 (0.68) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL1655099 | 0.89 | ABL1 (1.00) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL7465138 | 0.88 | ABL1 (0.80) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL14088818 | 0.88 | ABL1 (0.80) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL3758823 | 0.87 | MAPK8 (0.76) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL4712432 | 0.87 | ABL1 (0.61) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL4903328 | 0.86 | MAPK8 (0.81) | ABL1BCRPRKCASRCPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101228151-B | Salts of 4-methyl-N- [3- (4-methyl-imidazol-1-yl) -5-trifluoromethyl-phenyl ] -3- (4-pyridin-3-yl-pyrimidin-2-ylamino) -benzamide | NOVARTIS AG | 2013-01-09 | — | — | CN | claimed |
| CN-102267981-A | Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | — | 2011-12-07 | — | — | CN | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | claimed |
| CN-101228151-A | Salts of 4-methyl-N- [ 3- (4-methyl-imidazol-1-yl) -5-trifluoromethyl-phenyl ] -3- (4-pyridin-3-yl-pyrimidin-2-ylamino) -benzamide | NOVARTIS AG (CH) | 2008-07-23 | — | — | CN | claimed |
| CN-101228150-A | Crystalline forms of 4-methyl-N- [ 3- (4-methyl-imidazol-1-yl) -5-trifluoromethyl-phenyl ] -3- (4-pyridin-3-yl-pyrimidin-2-ylamino) -benzamide | NOVARTIS AG (CH) | 2008-07-23 | — | — | CN | claimed |
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | claimed |
| EP-1395261-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2004-03-10 | — | — | EP | claimed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | claimed |
| WO-2002093164-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-11-21 | — | — | WO | claimed |
| CN-114853734-A | Preparation method of nilotinib free base | 海南鑫开源医药科技有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20150290235-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB SCIENCE (FR) | 2015-10-15 | — | — | US | disclosed |
| EP-2922572-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB Science (FR) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079709-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB SCIENCE (FR) | 2014-05-30 | — | — | WO | disclosed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
| EP-1395261-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2004-03-10 | — | — | EP | disclosed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | disclosed |
| WO-2002093164-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | PRNP, PPM1D, PPM1F | ABL1 901/4885BCR 1338/4885PRKCA 138/4885 |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | ABL1 904/4885BCR 1230/4885PRKCA 121/4885 |
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | ABL1 2843/4885BCR 2315/4885PRKCA 2607/4885 |
| US-20150290235-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | DCK, ADK, DTYMK | ABL1 136/4885BCR 1534/4885PRKCA 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.